Statistics from Altmetric.com
Spinal muscular atrophies (SMA) are a genetically and clinically heterogeneous group of disorders predominantly of the anterior horn. While the large majority of recessive SMA cases can be explained by mutations in SMN1, the genetic basis of dominant SMA has remained largely elusive. Although mutations have been identified in >12 genes, mutations are found only in less than 30% of dominant SMA cases.1 Recently, BICD2 has been identified to cause dominant SMA.1–⇓3 Here, we provide additional evidence that BICD2 is a cause of dominant SMA and report detailed clinical, electrophysiological and MRI data from a three-generation family with cosegregation of a novel BICD2 mutation. These findings extend current notions of BICD2, demonstrating that it can present with adult-onset combined proximal and distal lower extremity SMA. Our clinical observations not only extend the phenotype of BICD2-related disease, but might also provide novel insights in the pathophysiology of the disease.
The 44-year-old German female index patient (III-2, figure 1A) presented with a 3-year history of a mild symmetric proximal (Medical Research Council (MRC) grade 4) and distal (MRC grade 3) paresis of lower extremities. While able to ambulate independently, she was unable to walk on heels and had difficulties walking on toes and climbing >10 stairs. There was areflexia of lower limbs, high-arched feet (figure 1C) and complete atrophy of the quadriceps muscle (figure 1D) without genu recurvatum. She recalled minor problems in jumping during sports at school, however had not sought medical …
Contributors MS: study concept and design, acquisition of data, writing of manuscript. LAM-C: acquisition of data, critical revision of the manuscript for important intellectual content. TL: acquisition of data, critical revision of the manuscript for important intellectual content. LS: analysis and interpretation; critical revision of the manuscript for important intellectual content. BW: acquisition of data, analysis and interpretation, study supervision, critical revision of the manuscript for important intellectual content.
Funding This work was supported by NeurOmics funded by the European Community's Seventh Framework Programme (FP7/2007–2013) (to LS and BW).
Competing interests MS received consulting fees from Actelion Pharmaceuticals Ltd.
Patient consent Obtained.
Ethics approval Ethics committee University of Tüingen, Germany.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.